Systematic (IUPAC) name | |
---|---|
gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Licence data | US FDA:link |
Pregnancy cat. | C(US) |
Legal status | POM (UK) ℞-only (US) |
Routes | IV |
Identifiers | |
CAS number | 138071-82-6 |
ATC code | V08CA09 |
PubChem | CID 72057 |
DrugBank | DB06703 |
UNII | 1BJ477IO2L |
KEGG | D07420 |
ChEMBL | CHEMBL1628503 |
Chemical data | |
Formula | C18H31GdN4O9 |
Mol. mass | 604.710 g/mol |
SMILES | eMolecules & PubChem |
(verify) |
(what is this?)
Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
It received marketing approval in Canada[1] and in the United States.[2][3][4]
As of 2007, it was the only GBCA approved at 1.0 molar concentrations.[5]
Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.[6]